CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis

Phase 3Brepocitinibbrepocitinib
Related Companies

Read the original article

Published by GlobeNewswire Pharma on August 26, 2026 3:11 PM

Read Original